Eisai
Eisai is a pharmaceutical company that researches and delivers medicines for patients.
Launch date
Employees
Market cap
AUD19.6b
Enterprise valuation
AUD17.3b (Public information from Sep 2024)
Share price
JPY5751
Tokyo Japan (HQ)
Financials
Estimates*
EUR | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|
Revenues | 4.5b | 5.3b | 5.2b | 5.2b | 5.4b | 5.9b | 6.2b |
% growth | (7 %) | 17 % | (2 %) | - | 3 % | 9 % | 6 % |
EBITDA | 616m | 645m | 560m | 650m | 673m | 765m | 809m |
% EBITDA margin | 14 % | 12 % | 11 % | 13 % | 13 % | 13 % | 13 % |
Profit | 295m | 336m | 388m | 297m | 314m | 426m | 465m |
% profit margin | 7 % | 6 % | 7 % | 6 % | 6 % | 7 % | 7 % |
EV / revenue | 3.0x | 1.9x | 2.7x | 2.2x | 2.0x | 1.8x | 1.7x |
EV / EBITDA | 22.3x | 15.3x | 25.1x | 17.6x | 16.1x | 14.1x | 13.3x |
Source: Dealroom estimates
Date | Investors | Amount | Round |
---|---|---|---|
N/A | N/A | IPO | |
$25.0m Valuation: $25.0m | Acquisition | ||
Total Funding | - |
Recent News about Eisai
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.